Diurnal
A pharmaceutical company creating therapeutic drugs used for the endocrine hormone area.
Launch date
Employees
Market cap
€57.3m
Enterprise valuation
€33m (Public information from Nov 2022)
Share price
£0.27245 DNL.L
Company register number 05237326
Cardiff Wales (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | 1.0m | 8.1m | - | - |
| % growth | - | - | 700 % | 1150 % | 713 % | - | - |
| EBITDA | (8.0m) | (10.0m) | (20.0m) | (20.0m) | (5.0m) | (13.1m) | (36.2m) |
| % EBITDA margin | - | (100000 %) | (25000 %) | (2000 %) | (62 %) | - | - |
| Profit | 5.0m | 9.0m | - | 10.0m | 5.0m | - | - |
| % profit margin | - | 90000 % | - | 1000 % | 62 % | - | - |
| R&D budget | - | - | <1m | <1m | 7.0m | - | - |
| R&D % of revenue | - | - | 88 % | 90 % | 86 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
£250k | Grant | ||
£600k | Debt | ||
£340k | Seed | ||
£6.0m | Early VC | ||
| N/A | N/A | IPO | |
| N/A | $44.6m | Post IPO Equity | |
N/A | Grant | ||
* | $56.5m | Acquisition | |
| Total Funding | €7.9m | ||
Related Content
Recent News about Diurnal
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.